221 related articles for article (PubMed ID: 27025622)
1. Doxycycline and Tigecycline: Two Friendly Drugs with a Low Association with Clostridium Difficile Infection.
Hung YP; Lee JC; Lin HJ; Liu HC; Wu YH; Tsai PJ; Ko WC
Antibiotics (Basel); 2015 Jun; 4(2):216-29. PubMed ID: 27025622
[TBL] [Abstract][Full Text] [Related]
2. Effects of tigecycline and vancomycin administration on established Clostridium difficile infection.
Theriot CM; Schumacher CA; Bassis CM; Seekatz AM; Young VB
Antimicrob Agents Chemother; 2015 Mar; 59(3):1596-604. PubMed ID: 25547352
[TBL] [Abstract][Full Text] [Related]
3. Tigecycline for the treatment of severe Clostridium difficile infection.
Larson KC; Belliveau PP; Spooner LM
Ann Pharmacother; 2011 Jul; 45(7-8):1005-10. PubMed ID: 21730279
[TBL] [Abstract][Full Text] [Related]
4. Tigecycline suppresses toxin A and B production and sporulation in Clostridium difficile.
Aldape MJ; Heeney DD; Bryant AE; Stevens DL
J Antimicrob Chemother; 2015 Jan; 70(1):153-9. PubMed ID: 25151204
[TBL] [Abstract][Full Text] [Related]
5. The outcome of patients with severe and severe-complicated Clostridium difficile infection treated with tigecycline combination therapy: a retrospective observational study.
Bishop EJ; Tiruvoipati R; Metcalfe J; Marshall C; Botha J; Kelley PG
Intern Med J; 2018 Jun; 48(6):651-660. PubMed ID: 29363242
[TBL] [Abstract][Full Text] [Related]
6. Alteration of the murine gastrointestinal microbiota by tigecycline leads to increased susceptibility to Clostridium difficile infection.
Bassis CM; Theriot CM; Young VB
Antimicrob Agents Chemother; 2014 May; 58(5):2767-74. PubMed ID: 24590475
[TBL] [Abstract][Full Text] [Related]
7. Tigecycline for the Treatment of Severe and Severe Complicated Clostridium difficile Infection.
Britt NS; Steed ME; Potter EM; Clough LA
Infect Dis Ther; 2014 Dec; 3(2):321-31. PubMed ID: 25466443
[TBL] [Abstract][Full Text] [Related]
8. The role of tigecycline in the management of Clostridium difficile infection: a retrospective cohort study.
Manea E; Sojo-Dorado J; Jipa RE; Benea SN; Rodríguez-Baño J; Hristea A
Clin Microbiol Infect; 2018 Feb; 24(2):180-184. PubMed ID: 28642147
[TBL] [Abstract][Full Text] [Related]
9. Use of intravenous tigecycline in patients with severe Clostridium difficile infection: a retrospective observational cohort study.
Gergely Szabo B; Kadar B; Szidonia Lenart K; Dezsenyi B; Kunovszki P; Fried K; Kamotsay K; Nikolova R; Prinz G
Clin Microbiol Infect; 2016 Dec; 22(12):990-995. PubMed ID: 27599690
[TBL] [Abstract][Full Text] [Related]
10. Tigecycline does not induce proliferation or cytotoxin production by epidemic Clostridium difficile strains in a human gut model.
Baines SD; Saxton K; Freeman J; Wilcox MH
J Antimicrob Chemother; 2006 Nov; 58(5):1062-5. PubMed ID: 17030519
[TBL] [Abstract][Full Text] [Related]
11. Antimicrobial susceptibility of Clostridium difficile isolates in Israel.
Tkhawkho L; Nitzan O; Pastukh N; Brodsky D; Jackson K; Peretz A
J Glob Antimicrob Resist; 2017 Sep; 10():161-164. PubMed ID: 28729205
[TBL] [Abstract][Full Text] [Related]
12. Use of tigecycline for the management of Clostridium difficile colitis in oncology patients and case series of breakthrough infections.
Brinda BJ; Pasikhova Y; Quilitz RE; Thai CM; Greene JN
J Hosp Infect; 2017 Apr; 95(4):426-432. PubMed ID: 28153556
[TBL] [Abstract][Full Text] [Related]
13. Is tigecycline a suitable option for Clostridium difficile infection? Evidence from the literature.
Di Bella S; Nisii C; Petrosillo N
Int J Antimicrob Agents; 2015 Jul; 46(1):8-12. PubMed ID: 25982915
[TBL] [Abstract][Full Text] [Related]
14. Comparison of in vitro activities of tigecycline, doxycycline, and tetracycline against the spirochete Borrelia burgdorferi.
Ates L; Hanssen-Hübner C; Norris DE; Richter D; Kraiczy P; Hunfeld KP
Ticks Tick Borne Dis; 2010 Mar; 1(1):30-4. PubMed ID: 21771509
[TBL] [Abstract][Full Text] [Related]
15. Tigecycline exhibits inhibitory activity against Clostridium difficile in the colon of mice and does not promote growth or toxin production.
Jump RL; Li Y; Pultz MJ; Kypriotakis G; Donskey CJ
Antimicrob Agents Chemother; 2011 Feb; 55(2):546-9. PubMed ID: 21135181
[TBL] [Abstract][Full Text] [Related]
16. [In Vitro Activities of Antimicrobials Against Toxigenic Clostridioides difficile Isolates Obtained in a University Training and Research Hospital in Turkey].
Sayın E; Bilgin H; Söyletir G; Ülger Toprak N
Mikrobiyol Bul; 2020 Jul; 54(3):368-377. PubMed ID: 32755514
[TBL] [Abstract][Full Text] [Related]
17. Role of doxycycline in Clostridium difficile infection acquisition.
Turner RB; Smith CB; Martello JL; Slain D
Ann Pharmacother; 2014 Jun; 48(6):772-6. PubMed ID: 24682682
[TBL] [Abstract][Full Text] [Related]
18. Intravenous Tigecycline Facilitates Cure of Severe Clostridium difficile Infection (CDI) After Failure of Standard Therapy: A Case Report and Literature Review of Tigecycline Use in CDI.
Navalkele BD; Lerner SA
Open Forum Infect Dis; 2016 Apr; 3(2):ofw094. PubMed ID: 27419166
[TBL] [Abstract][Full Text] [Related]
19. High in vitro activity of fidaxomicin against Clostridium difficile isolates from a university teaching hospital in China.
Cheng JW; Yang QW; Xiao M; Yu SY; Zhou ML; Kudinha T; Kong F; Liao JW; Xu YC
J Microbiol Immunol Infect; 2018 Jun; 51(3):411-416. PubMed ID: 28693926
[TBL] [Abstract][Full Text] [Related]
20. Fidaxomicin reduces early toxin A and B production and sporulation in Clostridium difficilein vitro.
Aldape MJ; Packham AE; Heeney DD; Rice SN; Bryant AE; Stevens DL
J Med Microbiol; 2017 Oct; 66(10):1393-1399. PubMed ID: 28893366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
